Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling
- 31 March 2005
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 53 (3), 241-252
- https://doi.org/10.1016/j.critrevonc.2004.10.004
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II StudyJournal of Clinical Oncology, 2004
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic ImplicationsJournal of Clinical Oncology, 2004
- Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant MelanomaJournal of Clinical Oncology, 2003
- Temozolomide for treating brain metastasesSeminars in Oncology, 2001
- Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cellsCell Death & Differentiation, 2001
- O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II studyInternational Journal of Cancer, 2000
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBritish Journal of Cancer, 2000
- The charing cross hospital experience with temozolomide in patients with gliomasEuropean Journal of Cancer, 1996
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal of Cancer, 1993
- O6-Methylguanine-DNA methyltransferase activity in human tumorsCarcinogenesis: Integrative Cancer Research, 1992